University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor

Uma Mahadevan, M.D.

Gastroenterologist

An expert in inflammatory bowel disease, particularly as it related to pregnancy and fertility, new drug trials and pouchitis, Dr. Uma Mahadevan serves as director of clinical research at the UCSF Center for Colitis and Crohn's disease. In addition to caring for patients with inflammatory bowel disease (IBD), she is interested in developing novel therapies for the condition, as well as investigating pregnancy and fertility outcomes in IBD.

Mahadevan received her medical degree from State University of New York and completed her residency in internal medicine at Mount Sinai Medical Center in New York. She then went on to complete her fellowship in gastroenterology at UCSF and inflammatory bowel disease at Mayo Clinic, Rochester, Minn. Her research on inflammatory bowel disease has been widely published in medical journals and books. Currently, Mahadevan holds the position of assistant clinical professor of medicine at UCSF.

Conditions & Treatments

Clinics

Gastroenterology at Mount Zion
2330 Post St., Suite 610
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Inflammatory Bowel Disease Center
2330 Post St., Sixth Floor
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

More about Uma Mahadevan

Additional Languages

Tamil

Education

State University of New York, Brooklyn College of Medicine 1995

Residencies

Mount Sinai Medical Center, Internal Medicine 1998

Fellowships

Mayo Clinic, Inflammatory Bowel Disease 2001
UCSF Medical Center, Gastroenterology 2001

Selected Research and Publications

  1. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011 Dec; 5(6):612-8.
  2. Leung Y, Heyman MB, Mahadevan U. Transitioning the adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis. 2011 Oct; 17(10):2169-73.
  3. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224.
  4. Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, Loke P. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med. 2010 Dec 1; 2(60):60ra88.
  5. van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010 Nov; 4(5):493-510.
  6. Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol. 2010 Jul; 6(4):643-57.
  7. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010 Jun; 16(6):925-32.
  8. Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut. 2010 Jun; 59(6):760-6.
  9. El-Nachef N, Terdiman J, Mahadevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010 May; 105(5):1210-1.
  10. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.
  11. Molloy JW, Kim E, Mahadevan U. Do side-by-side anastomoses decrease the risk of recurrence in Crohn's disease? Gastroenterology. 2010 May; 138(5):2010-2.
  12. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3.
  13. Mahadevan U. Pregnancy and inflammatory bowel disease. Med Clin North Am. 2010 Jan; 94(1):53-73.
  14. Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol. 2010 Jan; 105(1):219; author reply 219-20.
  15. Mahadevan U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am. 2009 Dec; 38(4):629-49.
  16. Sewell JL, Mahadevan U. Of blemishes and bowels: isotretinoin and inflammatory bowel disease. Gastroenterology. 2010 Jan; 138(1):392-4.
  17. Mahadevan U. Cervical neoplasia risk in IBD: truth or hysteria? Inflamm Bowel Dis. 2009 Nov; 15(11):1619-20.
  18. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009 Sep; 15(9):1399-409.
  19. McCabe JM, Mahadevan U, Vidyarthi A. An obscure harbinger. Difficult diagnosis of Crohn's Disease. Am J Med. 2009 Jun; 122(6):516-8.
  20. Sewell JL, Mahadevan U. A new answer to an old question: azathioprine withdrawal in quiescent Crohn's disease. Gastroenterology. 2009 Jul; 137(1):379-81.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.